Copyright Reports & Markets. All rights reserved.

Global Influenza Vaccine Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Influenza Vaccine Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Influenza Vaccine Market Size Growth Rate by Product
      • 1.4.2 Fluzone/Vaxigrip
      • 1.4.3 FluMist
      • 1.4.4 Fluarix and Flulaval
      • 1.4.5 Anflu
      • 1.4.6 Fluvax/Afluria
      • 1.4.7 Flucelvax and Fluvirin
    • 1.5 Market by End User
      • 1.5.1 Global Influenza Vaccine Market Size Growth Rate by End User
      • 1.5.2 Adults
      • 1.5.3 Pediatrics
      • 1.5.4 Senior Citizens
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Influenza Vaccine Market Size
      • 2.1.1 Global Influenza Vaccine Revenue 2014-2025
      • 2.1.2 Global Influenza Vaccine Sales 2014-2025
    • 2.2 Influenza Vaccine Growth Rate by Regions
      • 2.2.1 Global Influenza Vaccine Sales by Regions
      • 2.2.2 Global Influenza Vaccine Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Influenza Vaccine Sales by Manufacturers
      • 3.1.1 Influenza Vaccine Sales by Manufacturers
      • 3.1.2 Influenza Vaccine Sales Market Share by Manufacturers
      • 3.1.3 Global Influenza Vaccine Market Concentration Ratio (CR5 and HHI)
    • 3.2 Influenza Vaccine Revenue by Manufacturers
      • 3.2.1 Influenza Vaccine Revenue by Manufacturers (2014-2019)
      • 3.2.2 Influenza Vaccine Revenue Share by Manufacturers (2014-2019)
    • 3.3 Influenza Vaccine Price by Manufacturers
    • 3.4 Influenza Vaccine Manufacturing Base Distribution, Product Types
      • 3.4.1 Influenza Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Influenza Vaccine Product Type
      • 3.4.3 Date of International Manufacturers Enter into Influenza Vaccine Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Influenza Vaccine Sales by Product
    • 4.2 Global Influenza Vaccine Revenue by Product
    • 4.3 Influenza Vaccine Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Influenza Vaccine Breakdown Data by End User

    6 North America

    • 6.1 North America Influenza Vaccine by Countries
      • 6.1.1 North America Influenza Vaccine Sales by Countries
      • 6.1.2 North America Influenza Vaccine Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Influenza Vaccine by Product
    • 6.3 North America Influenza Vaccine by End User

    7 Europe

    • 7.1 Europe Influenza Vaccine by Countries
      • 7.1.1 Europe Influenza Vaccine Sales by Countries
      • 7.1.2 Europe Influenza Vaccine Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Influenza Vaccine by Product
    • 7.3 Europe Influenza Vaccine by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Influenza Vaccine by Countries
      • 8.1.1 Asia Pacific Influenza Vaccine Sales by Countries
      • 8.1.2 Asia Pacific Influenza Vaccine Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Influenza Vaccine by Product
    • 8.3 Asia Pacific Influenza Vaccine by End User

    9 Central & South America

    • 9.1 Central & South America Influenza Vaccine by Countries
      • 9.1.1 Central & South America Influenza Vaccine Sales by Countries
      • 9.1.2 Central & South America Influenza Vaccine Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Influenza Vaccine by Product
    • 9.3 Central & South America Influenza Vaccine by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Influenza Vaccine by Countries
      • 10.1.1 Middle East and Africa Influenza Vaccine Sales by Countries
      • 10.1.2 Middle East and Africa Influenza Vaccine Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Influenza Vaccine by Product
    • 10.3 Middle East and Africa Influenza Vaccine by End User

    11 Company Profiles

    • 11.1 AstraZeneca
      • 11.1.1 AstraZeneca Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 AstraZeneca Influenza Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 AstraZeneca Influenza Vaccine Products Offered
      • 11.1.5 AstraZeneca Recent Development
    • 11.2 CSL
      • 11.2.1 CSL Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 CSL Influenza Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 CSL Influenza Vaccine Products Offered
      • 11.2.5 CSL Recent Development
    • 11.3 GlaxoSmithKline
      • 11.3.1 GlaxoSmithKline Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 GlaxoSmithKline Influenza Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 GlaxoSmithKline Influenza Vaccine Products Offered
      • 11.3.5 GlaxoSmithKline Recent Development
    • 11.4 Sanofi
      • 11.4.1 Sanofi Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Sanofi Influenza Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Sanofi Influenza Vaccine Products Offered
      • 11.4.5 Sanofi Recent Development
    • 11.5 Altimmune
      • 11.5.1 Altimmune Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Altimmune Influenza Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Altimmune Influenza Vaccine Products Offered
      • 11.5.5 Altimmune Recent Development
    • 11.6 BionVax
      • 11.6.1 BionVax Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 BionVax Influenza Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 BionVax Influenza Vaccine Products Offered
      • 11.6.5 BionVax Recent Development
    • 11.7 FluGen
      • 11.7.1 FluGen Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 FluGen Influenza Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 FluGen Influenza Vaccine Products Offered
      • 11.7.5 FluGen Recent Development
    • 11.8 Folia Biotech
      • 11.8.1 Folia Biotech Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Folia Biotech Influenza Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Folia Biotech Influenza Vaccine Products Offered
      • 11.8.5 Folia Biotech Recent Development
    • 11.9 Genentech
      • 11.9.1 Genentech Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Genentech Influenza Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Genentech Influenza Vaccine Products Offered
      • 11.9.5 Genentech Recent Development
    • 11.10 Green Cross
      • 11.10.1 Green Cross Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Green Cross Influenza Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Green Cross Influenza Vaccine Products Offered
      • 11.10.5 Green Cross Recent Development
    • 11.11 Medicago
    • 11.12 Moderna Therapeutics
    • 11.13 Novavax
    • 11.14 Shijiazhuang Yiling Pharmaceutical
    • 11.15 SK Chemicals
    • 11.16 UNM Pharma
    • 11.17 Vaccitec

    12 Future Forecast

    • 12.1 Influenza Vaccine Market Forecast by Regions
      • 12.1.1 Global Influenza Vaccine Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Influenza Vaccine Revenue Forecast by Regions 2019-2025
    • 12.2 Influenza Vaccine Market Forecast by Product
      • 12.2.1 Global Influenza Vaccine Sales Forecast by Product 2019-2025
      • 12.2.2 Global Influenza Vaccine Revenue Forecast by Product 2019-2025
    • 12.3 Influenza Vaccine Market Forecast by End User
    • 12.4 North America Influenza Vaccine Forecast
    • 12.5 Europe Influenza Vaccine Forecast
    • 12.6 Asia Pacific Influenza Vaccine Forecast
    • 12.7 Central & South America Influenza Vaccine Forecast
    • 12.8 Middle East and Africa Influenza Vaccine Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Influenza Vaccine Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Influenza vaccines are vaccines that protect against infection by Influenza viruses. A new version of the vaccine is developed twice a year, as the Influenza virus rapidly changes. While their effectiveness varies from year to year, most provide modest to high protection against influenza.
      The European Centre for Disease Prevention and Control also recommends yearly vaccination of high risk groups. These groups include pregnant women, the elderly, children between six months and five years of age, those with other health problems, and those who work in healthcare.
      The global Influenza Vaccine market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Influenza Vaccine market based on company, product type, end user and key regions.

      This report studies the global market size of Influenza Vaccine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Influenza Vaccine in these regions.
      This research report categorizes the global Influenza Vaccine market by top players/brands, region, type and end user. This report also studies the global Influenza Vaccine market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      AstraZeneca
      CSL
      GlaxoSmithKline
      Sanofi
      Altimmune
      BionVax
      FluGen
      Folia Biotech
      Genentech
      Green Cross
      Medicago
      Moderna Therapeutics
      Novavax
      Shijiazhuang Yiling Pharmaceutical
      SK Chemicals
      UNM Pharma
      Vaccitec

      Market size by Product
      Fluzone/Vaxigrip
      FluMist
      Fluarix and Flulaval
      Anflu
      Fluvax/Afluria
      Flucelvax and Fluvirin
      Market size by End User
      Adults
      Pediatrics
      Senior Citizens

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Influenza Vaccine market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Influenza Vaccine market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Influenza Vaccine companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Influenza Vaccine submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Influenza Vaccine are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Influenza Vaccine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now